Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2007

View Archived Issues

Recent patents disclose novel analgesic agents

New treatments for cancer described in recent patents

Snapshots from the European Winter Conference on Brain Research

OxyADF is aversive in subjects with history of opioid abuse

Emergent to use VaxImmune in development of new anthrax vaccines

FDA extends review period for Frova menstrual migraine sNDA

Clearance for Spanish trial of P-144 for scleroderma

Enrollment completed in phase II trials for Amigal

Sanofi-aventis planning European launch of SoloSTAR disposable insulin pen

Trans-sodium crocetinate begins clinical testing

Neuroprotective effects of herbal medicines

Zolpidem improves motor, cognition performance in a patient with akinetic mutism

Sildenafil improves exercise capacity in idiopathic pulmonary fibrosis

Herpes simplex virus shows potential as a diagnostic tool for cancer

Tyrosine kinase inhibitors delay tumor growth in ocular melanoma model

Celecoxib reduces PanIN lesions and papilloma formation in a pancreatic cancer model

Cancer-associated pathways modulated by (S)-HDAC-42

Spectrum updates clinical progress of 2006

New targets for neurodegenerative diseases

Japanese launch for Certican tablets

Lialda now available

EGFR intron 1 status predicts sensitivity to erlotinib in pancreatic cancer cells

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...